検索結果

ntial cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed to improve both subjective symptoms and objective signs of DED through inhibition of TRPV1. A pivotal Phase III clinical trial ...

ntial cation channel subfamily V member 1 (TRPV1)*1 antagonist, designed to improve both subjective symptoms and objective signs of DED through inhibition of TRPV1. A pivotal Phase III clinical trial ...

Compliance System | Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

nstantly alert, paying attention to views and voices within the company so as to uphold a corporate system and culture that are genuinely effective. In the event of any incident arising that goes agai...

Our Initiatives for Society/Environment | About Senju | SENJU Pharmaceutical

ed 210,000 yen through the Eye and ENT Association for The Himalayan(EArTH) under the matching gift system operating between our employees and the company. In the wake of the 2016 Kumamoto Earthquake ...

Research and Development System | Research & Development | SENJU Pharmaceutica

organism, we evaluate its absorption, tissue distribution, metabolism, and excretion. We assess the systemic and ocular pharmacokinetics of eye drops and intraocular injections. Pharmacokinetics is st...